Cat. #152857
D34 Cell Line
Cat. #: 152857
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Tissue: Tongue
Disease: Cancer
Model: Tumour line
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Paul Harrison
Institute: Cancer Research UK, Glasgow: The Beatson Institute
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: D34 Cell Line
- Cancer: Blood cancer
- Cancers detailed: Dysplasia;Leukoplakia
- Research fields: Cancer;Drug development
- Organism: Human
- Tissue: Tongue
- Disease: Cancer
- Model: Tumour line
- Conditional: No
- Description: D34 Cell Line is derived from a leukoplakia biopsy. The cell line was notable in its proliferative capacity, considered immortal after having completed more than 100 PDs (population doublings ) when maintained on a feeder layer of irradiated 3T3 fibroblasts. D34 was categorised as having a moderate dysplasia pathology.
- Production details: Biopsies were trypsinized and cultured until a growing population of cells was obtained in a 9-cm plate and then passaged once to give a stock culture that was frozen. All cells were maintained on irradiated 3T3 feeders, in 10H medium. The 3T3 feeder layer was removed by treatment with 0.02% EDTA prior to RNA and protein extraction.
- Cellosaurus id: CVCL_HF98
Handling
- Format: Frozen
- Growth medium: As per Cancer Res. 1997 Sep 15;57(18):3886-9. All cells were maintained on irradiated 3T3 feeders, in 10H medium (DMEM plus 10% FCS without added growth factors except hydrocortisone).
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
Related Tools
- Related tools: D38 Cell Line
References
- McGregor et al. 2002. Cancer Res. 62(16):4757-66. PMID: 12183435.
- Molecular changes associated with oral dysplasia progression and acquisition of immortality: potential for its reversal by 5-azacytidine.
